EP0598896A1 - Utilisation de l'amidon-iode comme agent de conservation - Google Patents

Utilisation de l'amidon-iode comme agent de conservation

Info

Publication number
EP0598896A1
EP0598896A1 EP93916472A EP93916472A EP0598896A1 EP 0598896 A1 EP0598896 A1 EP 0598896A1 EP 93916472 A EP93916472 A EP 93916472A EP 93916472 A EP93916472 A EP 93916472A EP 0598896 A1 EP0598896 A1 EP 0598896A1
Authority
EP
European Patent Office
Prior art keywords
iodine
starch
liquid
blood
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93916472A
Other languages
German (de)
English (en)
Inventor
Edward Shanbrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0598896A1 publication Critical patent/EP0598896A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • A01N59/12—Iodine, e.g. iodophors; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates to the treatment and preservation of blood and blood derivatives, the treatment and preparation of other body tissues and cells, the treatment and preparation of tissue cultures and tissue culture products, and the preparation of laboratory reagents, standards and samples.
  • starch hereinafter, unless otherwise indicated by context, are used in the treatment of treating biological materials. Thereafter a physiologically compatible reducing agent such as an ascorbate salt, as an additive or on a solid support, e.g. in a bed or filter of solid albumin, starch, povidone, etc, may be used to remove the last traces of biocidal iodine.
  • a physiologically compatible reducing agent such as an ascorbate salt, as an additive or on a solid support, e.g. in a bed or filter of solid albumin, starch, povidone, etc, may be used to remove the last traces of biocidal iodine.
  • This invention may, thus, be used to kill or inactivate virus, bacteria, chlamydia, rickettsia, mycoplasma and other potentially pathogenic microorganisms and to remove all biocidal iodine.
  • Iodine was officially recognized by the Pharmacopeia of the United States in 1930, also as tincture iodine (tincture of iodine) and linimentum iodi (liniment of iodine).
  • Clinicians and microbiologists described a great number of experimental data and clinical applications, which can be found in numerous surveys.
  • iodine it was ascertained early that it also possesses properties unsuitable for practical application, including, for example, the fact that iodine has an unpleasant odor.
  • N-H functions that are parts of some amino acids (e.g., lysine, histidine, arginine) and the bases of nucleotides (adenine, cytosine, and guanine) forming the corresponding N-iododerivatives.
  • amino acids e.g., lysine, histidine, arginine
  • nucleotides adenine, cytosine, and guanine
  • Iodine is used widely in human medicine is the disinfection of skin, (e.g., the preoperative preparations of the skin, the surgical disinfection of hands, the disinfection of the perineum prior to delivery, and the disinfection of the skin prior to infections and transfusions). Iodine preparations are also used for therapeutic purposes, e.g., the treatment of infected and burned skin but is a strong irritant. Iodine has also been used for the disinfection of medical equipment, such as catgut, catheters, knife blades, ampules, plastic items, rubber goods, brushes, multiple-dose vials, and thermometers.
  • medical equipment such as catgut, catheters, knife blades, ampules, plastic items, rubber goods, brushes, multiple-dose vials, and thermometers.
  • oxidizing iodine including "compounds incorporating molecules of biocidal iodine” e.g. absorbed or grafted on a purified vegetable carbon, as blood-contacting reagents having bactericidal and bacteriostatic action are mentioned in passing in connection with an autotransfuser device in U.S. Patent 4,898,572, Surugue nee Lasnier, et al but without any explanation or elucidation.
  • Iodine is an excellent, prompt, effective microbicide with a broad range of action that includes almost all of the important health-related microorganisms, such as enteric bacteria, enteric viruses, bacterial viruses, and protozoan cysts, if the sometimes severe limitations inherent in its use are overcome.
  • Mycobacteria and the spores of bacilli and clostridia can also be killed by iodine.
  • iodine also exhibits a fungicidal and trichomonacidal activity.
  • varying amounts of iodine are necessary to achieve complete disinfection of the different classes or organisms.
  • the published data on the disinfecting effect of iodine correspond only to a small extent. In particular, the published killing time os spores and viruses are widely disparate.
  • iodine On a weight basis, iodine can inactivate viruses more completely over a wide range of water quality than other halogens.
  • iodine is the cysticide of choice because it does not produce side reactions that interfere with its disinfecting properties.
  • Iodine would require the smallest mg/L dosage compared to chlorine or bromine to "break any water” to provide a free residual.
  • I 2 is 2 to 3 times as cysticidal and 6 times as sporicidal as HOI, while HOI is at least 40 times as virucidal as I 2 .
  • This behavior is explained on the one hand by the higher diffusibility of molecular iodine through the cell walls of cysts and spores and on the other hand by the higher biocidal power of HOI.
  • starch-iodine complexes have some biocidal activity, although no comprehensive studies of this activity have been identified.
  • Solid beads of cross-linked beads of starch-iodine that absorb moisture from wounds, etc., and also provide a source of iodine are well-known; see, e.g., Holloway, G. Allen, Jr.; Johansen, Kaj H.; Barnes, Robert W.; Pierce, George E., Multicenter trial of cadexomer iodine to treat venous stasis ulcer, Western Journal of Medicine. vl51 nl, p35(4), July, 1989.
  • Cadexomer iodine is a starch polymer bead with iodine attached to the polymer. This type of polymer bead kills bacteria with the iodine and is used in the treatment of open wounds and venous stasis ulcers.
  • Cadexomer iodine (IODOSORB® PERSTORP CARBOTEC®, Perstorp, Sweden]), is a starch polymer bead similar to dextranomer but with iodide (0.9% weight per weight) bonded to the polymer. When fluid contacts the beads, substantial amounts of fluid—as much as 6 ml per gram of cadexomer iodine—are absorbed, as well as bacteria within the fluid.
  • Bonded iodide becomes bactericidal in this milieu.
  • Other somewhat limited descriptions of the use of starch-iodine have also been published.
  • Glushankof S I, et al, Russian patent SU 1204575 describes compositions for purificationn and decontamination of water that contains starch, aluminium sulphate, iodine and activated charcoal to produce drinking water from open reservoirs in field conditions.
  • a starch-based disinfectant composition prepared by treating starch suspension with potassium permanganate followed by a solution of iodine in potassium permanganate is described by Tatarov P G, et. al., Russian patent SU 979363 821207.
  • Iodine starch for disinfection is described by Mochnacz, W. et. al., Ptitsevodstvo, 1980, 11, p. 37; Zh.. Vet. 1981, Abstr. No. 38226 .
  • soluble organo-iodine compounds in water purification is, of course, well-known.
  • One of the more popular water purifiers is tetraglycine hydroperiodide, which is widely used because of its effectiveness against giardia. Iodine has also been used to treat swimming pools, etc., but is objectionable because it irritates the eyes and stains the pool walls an unattractive yellow color.
  • Those who deal with blood and other invasively obtained body fluid samples risk infection from the samples.
  • Those at risk include the doctor, nurse or clinical technician who takes the sample, the technicians who handle the sample and who use the sample in conducting analyses and tests, those who handle the sampling and testing equipment and apparatus, and the entire chain of individuals who attend to the disposal of sampling apparatus and the like, from the individuals who pick up the used apparatus through those who ultimately dispose of the apparatus, usually in specially designed high temperature furnaces.
  • the risk is substantial, as evidenced by the fact that nearly all health care professionals with long experience carry the Epstein-Barr virus (EBV) and/or cytomegalovirus
  • EBV Epstein-Barr virus
  • cytomegalovirus cytomegalovirus
  • CMV chronic myelogenous virus
  • HAV human immunodeficiency virus
  • Yersinia enterocolitica which is become a serious contaminant, surpassing Salmonella and Campy lob acter as a cause of acute bacterial gastroenteritis.
  • a significant increase in transfusion related infections of Y . enterocolitica has been reported, Tipple, et al., Transfusion 30, 3, p.207 (1990).
  • Y. enterocolitica and other bacteria which propagate at relatively low temperatures, e.g. Staphylococcus epidermidis and Legionella pneumophila present, potentially, a serious threat in blood products.
  • molecular iodine e.g. povidone-I 2
  • Introduction of molecular iodine, e.g. povidone-I 2 at an early stage in processing of blood products greatly reduces or eliminates the pyrogen-load of the ultimate product or fraction.
  • Protozoa give rise to many diseases, some of great medical and economic importance. Examples of such protozoa are the genus Plasmodium, e.g. P. falciparum, P. malariae, P. ovale and P. vivax, which causes malaria, Trypanosoma, which causes Chagas 1 disease, and Leishmania, which cause a variety of leishmaniasis.
  • the method of this invention is effective in eliminating these causative organisms in blood and blood products.
  • this invention is applicable to the treatment of donated blood and products produced from blood, tissues and fluids for inactivating virus, bacteria, chlamydia, rickettsia, mycoplasma and other potentially pathogenic microorganisms.
  • CMV cytomegalovirus
  • Herpesviruses represent a very large group of viruses which are responsible for, or involved in, cold sores, shingles, a venereal disease, mononucleosis, eye infections, birth defects and probably several cancers.
  • the present invention is also useful in preventing the transmission of human immunodeficiency virus (HIV). While testing has made blood products safer than it was a decade ago, the complete elimination of HIV contaminated blood and blood products has not been possible using present knowledge and technology.
  • blood means whole blood and blood fractions, components, and products of blood, unless “whole blood” or a specific blood derivative, e.g. a blood fraction, component or product of blood is stated.
  • blood derivatives mean blood components such as blood cell concentrates (red blood cells, platelets, etc.), plasma, and serum and products and factors prepared from blood such as albumin and the blood factors.
  • Body tissues and cells means any tissue(s), organ(s) or cells or fluids which contain tissue(s), organ(s) or cells of animal origin.
  • body tissues and cells include blood and the cellular components of blood; however, for the most part, simply for clarity in presentation, blood is treated as a separate application of the invention.
  • body tissues and cells include bone marrow, kidneys, cornea, heart valves, tendons, ligaments, skin, homograft or xenograft implants and prosthesis generally.
  • Tissue and cell cultures means cells and tissues grown or enhanced in culture media and the culture media per se, but not including nutrients intended for use in cell cultures.
  • Examples of a cultured tissue is cultured skin tissue for use in burn victims, cells and cellular products prepared by standard biological and/or genetic engineering techniques are other examples of tissue cultures.
  • Laboratory reagents and standards as used in this specification and the claims, means reagents and standards produced from or comprising human or animal fluids, cells or tissues.
  • red blood cell panel utilized for typing blood, control sera and chemistry controls.
  • Samples of tissues and fluids to be tested include samples of blood, urine, sputum, cell smears, etc. While the term “donor” is not usually applied to the individual from whom such samples are acquired, that term, “donor” will be used here in a more general sense to include the individual from whom any blood, tissue, cells or fluid is obtained for any purpose, and such term will be used to refer even to an unwilling donor.
  • tissue culture If a tissue is explanted into the culture media for the purpose of propagating its cells, the procedure is called tissue culture whereas the explanting of individual cells into culture media would be called cell culture; however, both procedures are often referred to by the term "tissue culture” procedures without differentiation, unless the distinction is critical for some ancillary reason. This general usage of the term is employed here.
  • Tissue cultured cells are extremely fragile in many ways, having exacting requirements not only as to nutrients but also to the amount and type of resident organisms which can be tolerated, and culture media are highly susceptible to bacterial and/or viral infection. It is, generally, impossible to define with precision the exact materials required to propagate a given cell line and, therefore, it is common practice to use media based upon or containing serum and to add nutrient serum as needed during the cell propagation.
  • Bovine serum from adult animals may be suitable in some instances, but fetal bovine serum (FBS) (sometimes referred to as fetal calf serum (FCS)) is required for the safe propagation of many cell lines, and where high purity is critical. Even the use of FBS is not, however, a guarantee of freedom from infective agents.
  • FBS fetal bovine serum
  • FCS fetal calf serum
  • Serum filtration is a common step in reducing the load of infectious organisms in serum, but serum quality can be damaged by filtration if significant amounts of serum components are adsorbed to the filters or if macromolecules are sheared. Shearing of macromolecules during filtration occurs generally when tangential flow filtration is used and turbulence develops.
  • the present invention encompases processes of treating a liquid composition that contains bacteria, virus, or other pathogenic organisms to sterilized the same by reaction with starch-iodine in the liquid phase or contacting the liquid with starch-iodine such as passing the liquid through solid starch-iodine filters or columns.
  • Starch-iodine may be iodine complexed with essentially the entire starch molecule, of any of the great variety of starches available from different sources, or with a polysacharide component, or derivative thereof, of starch, or an equivalent polysacharide, that binds to starch, amylose an amylopectin being the most widely available of these components.
  • the solution can be passed into contact with solid starch, e.g. filtered through a bed or column of solid starch particles that are less than saturated with iodine, preferably having no more than a trace of iodine or another iodine absorbing material, such as cross-linked povidone to remove the excess iodine.
  • a reducing agent such as a reducing sugar, ascorbate, sodium sulfite, etc., may be added to eliminate the last traces of biocidal iodine. Reducing sugars, ascorbic acid (Vitamin C) and its salts, and sodium sulfite are well-known, readily available reducing agents that are physiologically acceptable. However, any physiologically acceptable reducing agents may be used.
  • the invention is embodied in a method of disinfecting biological materials.
  • the steps of the method include treating biological material before separation of the components thereof with starch-iodine to provide from a concentration of 0.1 w /o to 5 w /o starch-iodine in said material before separation of the components thereof.
  • a derivative of the material resulting from the preceding step is prepared and, optionally, also treated with starch-iodine to provide from 0.1 w /o to 5 w /o starch-iodine in the derivative.
  • the derivative may be treated by addition of a physiologically acceptable reducing agent or contact with cross-linked PVP to reduce or remove residual iodine.
  • Also included in the invention is the improved method of treating patients with plasma comprising the steps of collecting plasma from a donor, and thereafter infusing the plasma into the patient to be treated, of mixing the plasma with starch-iodine sufficient to resulting a starch-iodine a concentration of from about 0.1 w /o to about 5 w /o, and allowing contact of said plasma with said starch-iodine for at least about one-half minute sufficient to inactivate or destroy infective pathogenic microbes in the plasma and optionally thereafter removing biocidal iodine from the resulting mixture by passing said mixture into intimate contact with cross-linked PVP or albumin or adding a physiologically acceptable reducing agent.
  • the apparatus is in the form of a liquid container having, in use an upper reservoir portion for holding said liquid and a lower elutriation portion for recovering liquid and structure defining first and second beds of particulate matter, the first bed comprising substantially insoluble starch-iodine and the second bed consisting essentially of substantially insoluble PVP, starch or albumin; the beds being so formed and configured as to permit the passage of the liquid therethrough in intimate contact with the surfaces of the particles forming the respective beds.
  • the first bed may be cross-linked PVP.
  • the apparatus may comprising a third layer between the first and second layers, the third layer comprising substantially insoluble PVP hydrogen peroxide particulate matter.
  • the apparatus may contain a layer of particulate matter comprising an iodine reducing agent.
  • a layer of soluble starch-iodine may be provided on the first layer in the liquid reservoir. All or only part of the layers, after the first and second layers, may be provided.
  • One method of sterilizing an implantable tissue in accordance with this invention comprises placing tissue that is physiologically acceptable for implantation into a human patient into a vacuum chamber, evacuating the chamber and maintaining a vacuum on the chamber for a period long enough to extract at least about one-half of the unbound water originally present in said tissue, and introducing into the vacuum chamber a solution of starch-iodine for thereby reconstituting into the tissue said solution in place of the water that was vacuum extracted.
  • iodine may be removed by washing or reconstituting the tissue with a reducing agent such as ascorbic acid or a salt thereof or sodium sulfite, for example.
  • Figure 1 depicts an apparatus for contacting a liquid material with starch-iodine and with either or both of (a) an iodine absorbing material and/or (b) an iodine reducing material, and for providing other materials for processing biological liquids, in particular, according to this invention.
  • Figure 2 depicts, largely schematically, an apparatus for treating solid tissue samples.
  • Starch-iodine may be prepared in any of a large number of methods. Substantially pure starch, that may have traces of other biological materials or be essentially free of contaminants is available commercially. Amylose and amylopectin, components of starch that are encompassed in the term "starch” as used in the general sense indicated above are also available in high purity. The chemistry of starch and polysacharides generally is well-developed and a large number of high purity starch and polysacharide compositions are available commercially.
  • starch-iodine optionally followed by treatment with a physiologically acceptable reducing agent for the manufacture of a medicament
  • a medicament may, for example, consist essentially of blood cells in plasma or another carrier liquid.
  • Such medicaments may be used for the treatment of disorders wherein the patient requires the transfusion of blood cells.
  • Starch-iodine is added in an amount in excess of that required to kill or inactivate all microbes is added.
  • Starch-iodine may comprise, for example, from about 0.01 to 10 weight percent, preferably from 0.1 w /o to 5 w /o of the medicament.
  • the starch-iodine is allowed to remain in contact with the blood cells or plasma, or other biological material being prepared to be a medicament, for a period of at least about a half a minute sufficient to kill the microbes, but not long enough to denature or otherwise injure the biological material. Usually, contact of under an hour is preferred. Accordingly, the contact times will be referred to as from one-half minute to one hour with the caveat that longer contact is not necessary or beneficial and may result in injury to the biological, but would, nevertheless, be within the scope of the invention.
  • the reducing agent is then added in an amount to reduce substantially all iodine. The maximum amount of reducing agent required is easily calculated.
  • the actual amount normally required, to which a safety margin amount will be added, is determined by an iodine assay on typical batches using known, routine procedures.
  • a second treatment as described may be performed to assure total sterilization, if desired.
  • a second similar treatment may be performed on a product or fraction of the initial biological material treated as described above.
  • starch-iodine and a physiologically acceptable iodine absorbent material for the manufacture of a medicament is contemplated by this invention.
  • a medicament may, for example, consist essentially of blood cells in plasma or another carrier liquid.
  • Such medicaments may be used for the treatment of disorders wherein the patient requires the transfusion of blood cells.
  • starch-iodine in an amount in excess of that required to kill or inactivate all microbes is added.
  • Starch-iodine may comprise, for example, from about 0.01 to 10 weight percent, preferably from 0.1 w /o to 5 w /o of the medicament.
  • the starch-iodine is allowed to remain in contact with the blood cells or plasma, or other biological material being prepared to be a medicament, for a period of at least about a half a minute sufficient to kill the microbes, but not long enough to denature or otherwise injure the biological material. Usually, contact of under an hour is preferred. Accordingly, the contact times will be referred to as from one-half minute to one hour with the caveat that longer contact is not necessary or beneficial and may result in injury to the biological, but would, nevertheless, be within the scope of the invention.
  • the mixture resulting from the above is then contacted with an iodine absorbing reagent such as cross-linked PVP, or coagulated albumin or solid starch, to remove the iodine.
  • an iodine absorbing reagent such as cross-linked PVP, or coagulated albumin or solid starch
  • a reducing agent may thereafter be added in an amount to reduce any iodine that may not have been absorbed.
  • the contact with the iodine absorbing material is preferably accomplished by passing the material undergoing treatment through a layer, i.e. a bed or filter, of solid, substantially insoluble albumin or starch.
  • a second treatment as described may be performed to assure total sterilization, if desired.
  • a second similar treatment may be performed on a product or fraction of the initial biological material treated as described above.
  • the "addition" of a reducing agent to the material undergoing treatment may be accomplished by passing the material through a layer of substantially insoluble material that has active reducing sites thereon or equilibrates with the liquid material undergoing treatment to partially dissolve into such liquid, or make readily available in said liquid (as by swelling, for example) reducing moieties.
  • a bed of beads or fibers, for example, that expose on the surface thereof reducing sugar moieties may be used very conveniently.
  • Figure 1 depicts an apparatus for contacting a liquid material with starch-iodine and with either or both of (a) an iodine absorbing material and/or (b) an iodine reducing material, and for providing other materials for processing biological liquids, in particular, according to this invention.
  • the apparatus being shown and described in a generally schematic fashion, may be in any of many configurations. The only significant structure, insofar as this invention relates is to the arrangement of the layers
  • the apparatus 10 may be viewed as a filter funnel or a column.
  • the apparatus comprises cylindrical portion 12 that, in part, defines a reservoir portion.
  • the reservoir may be large or very small as desired.
  • the apparatus in the configuration depicted comprises a second, smaller cylindrical tube portion 14 and a conical transition zone 16 connecting the two cylindrical portions as is conventional in funnel manufacture. It is again emphasized, however, that it is immaterial whether the apparatus defines a reservoir and or funnel portion of any particular size or configuration.
  • the apparatus defines a first layer 20 and a second layer 22.
  • the first layer is made up of substantially insoluble starch-iodine. This layer is described as being made up of particulate materials in that the use or particulates in one way or another is usually involved. Particles of solid, insoluble starch-iodine, e.g. cross-linked starch-iodine, in the form of a layer or bed of particles, either supported directly by a layer below or by way of another support, e.g. being bonded to or entrapped within a layer of fibers or particles, is contemplated.
  • the first layer may also contain some soluble starch-iodine. A frit made of particles bound together adhesively, by heat or pressure would also be within the disclosure and invention.
  • the starch-iodine may be formed in situ by iodinating a layer of starch or the layer may be made up of pre-synthesized starch-iodine.
  • the second layer is downstream of the first layer, i.e. the liquid to be treated flows through the first layer and then the second layer.
  • the second layer may comprise an insoluble iodine absorbent, e.g. cross-linked povidone, or insolublized albumin or starch, or an iodine reducing agent, or a mixture of both, or be a multiple sub-layer structure with a sublayer of iodine absorbent first and then a sublayer of iodine reductant.
  • the layer may be a self- supporting frit or other structure or may be supported by a support or other layer.
  • the essential function of the apparatus is to cause a liquid that is to be treated to pass, with or without cells or other particles therein, first through a layer of starch-iodine and, thereafter, to contact such liquid with absorbent to remove the iodine and/or reductant to reduce the iodine.
  • the layers may be quite deep or quite thin, adjacent each other or spaced from each other, as is necessary or desirable to provide adequate contact of the liquid with each of the layers or beds.
  • the liquid container that is generally defined by the overall apparatus in the simplified, schematic example of Figure 1, and has an upper or liquid inflow reservoir portion for holding liquid to be treated. This may be a very small reservoir or quite large. The reservoir may displaced from the beds or layers by a very large distance, though this is not generally beneficial.
  • the apparatus has a lower or elutriation or recovery portion for recovering liquid that has been treated. Between these portions, first and second beds of particulate matter are defined by suitable structure.
  • the first bed or layer comprises substantially insoluble starch-iodine.
  • the second bed consists essentially of substantially insoluble albumin or starch, or other iodine absorbent, and/or iodine reducing agent.
  • the beds are so formed and configured as to permit the passage of the liquid therethrough in intimate contact with the surfaces of the particles forming the respective beds.
  • the usual and most common iodine absorbent is cross-linked povidone.
  • the apparatus may desirably further comprise a third layer 24 between the first and second layers.
  • the third layer comprises substantially insoluble povidone hydrogen peroxide particulate matter. The presence of the third layer entraps and regenerates iodine and significantly increases the biocidal activity of iodine.
  • a fourth layer 26, which may be in the form of a sublayer within the second layer, comprising particulate iodine reducing agent may be provided downstream from the second layer to provide for the reduction of any residual iodine from I 2 to iodide, or, if reduction is earlier provided, to add a safety step to assure that all biocidal iodine has been reduced.
  • a fifth layer 28 of soluble starch-iodine on the first layer in the liquid reservoir may be desirable to provide a fifth layer 28 of soluble starch-iodine on the first layer in the liquid reservoir to permit the actual dissolution into the liquid of substantial amounts of starch-iodine and thereby provide a greater reservoir of more available iodine to the liquid.
  • the first and second layers are essential to the full and proper functioning of the apparatus. After those layers or beds, however, any number of additional layers or additives may be provided, so long as they do not interfere with the combined function of the first and second beds or layers.
  • All of the layers just described may, conveniently but not necessarily, be supported by a layer 30 that may be a frit, a filter paper or a porous layer.
  • the thickness of the beds may be the same or greatly different. It is a simple matter to calculate contact time in a column and to provide suitable beds of materials therein.
  • any of the beds may be made up the active material, e.g. starch-iodine, reducing sugar, etc., attached to carrier particles, such as ground glass, charcoal, ion exchange resin, cellulose derivatives, etc.
  • carrier particles such as ground glass, charcoal, ion exchange resin, cellulose derivatives, etc.
  • the particulate matter may, in a preferred form, consist essentially of particles having a diameter of from about 10 to about 100 microns, but any size that permits suitable flow rates and assures intimate contact may be used.
  • starch-iodine and a physiologically acceptable reducing agent for the manufacture of transfusion biological material from one human or mammal for transfusion of such material to another human or mammal, or the transplant or transfusion biological material is a part of this invention.
  • the transfusion or transplant is disinfected with a starch-iodine solution having concentration of from about 0.01 to 10 weight percent, preferably 0.1 /o to 5 w /o, and thereafter treated with the reducing agent to reduce the residual iodine.
  • Liquid materials may be treated in any suitable manner, such as has been described. Solid tissue samples may be treated simply be soaking, by infusing or by vacuum infusing.
  • Figure 2 depicts, largely schematically, an apparatus for treating solid tissue samples.
  • the apparatus comprises a chamber system 100 capable of withstanding the forces of a vacuum.
  • a cylinder 102 is closed at the respective ends by end covers 104 and 106, the end 106 being removable to gain access to the inside of the chamber.
  • a portion 108 of the end 106 may be slipped into the cylinder 102 and sealed using "O" rings, etc., to provide a vacuum tight seal.
  • a vacuum line 110 through valve 112 and line 114 permits evacuation of the chamber.
  • An input line 120, coupled to valve 122 and line 124 permits the introduction of liquid into the chamber.
  • a platform 126 secured to the end 106, supports a tissue sample 130.
  • Implantable tissues may be treated to kill microbes, i.e. "sterilized" by placing tissue that is physiologically acceptable for implantation into a human patient into a vacuum chamber, evacuating the chamber and maintaining a vacuum for a period long enough to extract at least about one-half of the unbound water originally present in said tissue and then introducing into said vacuum chamber a solution of starch-iodine for thereby reconstituting into the tissue said solution in place of the water that was vacuum extracted.
  • the thus treated tissue may then be soaked in a solution of an physiologically acceptable iodine reducing agent.
  • the chamber may again be evacuated to extract the starch-iodine solution from the tissue and a solution of physiologically acceptable iodine reducing agent introduced into the vacuum chamber for saturating the tissue for reducing any residual iodine.
  • the invention may comprise treating blood before separation of the components thereof with starch-iodine to provide from a concentration of from about 0.01 to 10 weight percent, preferably 0.1 w /o to 5 w /o, starch-iodine in the blood, preparing a derivative of the blood from step, treating the derivative with starch-iodine to provide from about 0.01 to 10 weight percent, preferably 0.1 /o to 5 w /o, iodine in the derivative thereafter treating the derivative by addition of a physiologically acceptable reducing agent or contact with cross-linked PVP to reduce or remove residual iodine.
  • Infective pathogenic microorganisms are believed to be inactivated when starch-iodine is used in solution to perfuse tissues and organs after removal from the donor and before transplantation to the recipient.
  • the perfusion solution comprises starch-iodine in a concentration of from about 0.01 to 10 weight percent, preferably O.l w /o to about 5 w /o (100 to 5000 ppm I 2 ), preferably from about 0.25 w /o to about 2 w /o.
  • the material to be purified is a liquid or cells carried in a liquid
  • a bed e.g. the conventional filter structure of solid particles on a porous or foraminous support
  • solid particles of starch-iodine of suitable size or by contacting the liquid and/or the cells in the liquid with particles or a membrane or surface of solid starch-iodine.
  • the particles must be large enough to permit intimate contact without entrapping or binding the cells.
  • the liquid may then be passed through a layer or in contact with solid phase starch-iodine to assure complete biocidal effect.
  • the liquid or cell-bearing liquid is contacted with the solid starch-iodine. This may be done most efficiently, in most cases, by passing the liquid through a settled or fluidized or packed bed of starch-iodine particles; however, such approaches will not, ordinarily, be suitable for treating cell-bearing liquids.
  • Cell-bearing liquids may be treated by mixing the particles in a container of the liquid or passing the liquid over a surface of the starch-iodine material, e.g. over a multiple-plate array of sheets of such material.
  • the starch-iodine may be washed and the iodine content therein regenerated between uses.
  • reducing agent e.g. a reducing sugar (or mixtures of reducing sugars), ascorbic acid or ascorbate, a sulfite, e.g. sodium sulfite, etc. in which the agent is in a concentration of 0.001 to 1 percent is suitable and such is implicit unless otherwise noted.
  • Solvent extraction of iodine with a solvent for iodine that is substantially inert to blood and biological materials generally may also be used to remove iodine.
  • N-heptane is a good solvent for iodine and has minimal effect, on short exposure, to blood and blood cells. Close n-alkane analogs and vegetable oils may also be used. Cotton seed oil, corn oil, etc.
  • the solvent extraction may be carried out in any suitable vessel that will permit intimate mixing of the blood and solvent and decantation of the hydrophobic phase from the top or withdrawal of the blood or biological liquid from the bottom.
  • the process results in transfusion quality whole blood that is safe, being free of pathogenic microbes, and which is also free of any added chemicals except for iodide
  • This invention finds application in medicine and veterinary science.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Traitement et conservation du sang, des dérivés du sang et d'autres liquides, tissus et cellules biologiques à l'aide d'amidon-iode et neutralisation du potentiel biocide de l'iode de manière à détruire les microorganismes pathogènes sans altérer l'utilité de ces liquides, tissus ou cellules.
EP93916472A 1992-06-11 1993-06-09 Utilisation de l'amidon-iode comme agent de conservation Withdrawn EP0598896A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87884592A 1992-06-11 1992-06-11
US878845 1992-06-11
PCT/US1993/005519 WO1993025268A1 (fr) 1992-06-11 1993-06-09 Utilisation de l'amidon-iode comme agent de conservation

Publications (1)

Publication Number Publication Date
EP0598896A1 true EP0598896A1 (fr) 1994-06-01

Family

ID=25372963

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93916472A Withdrawn EP0598896A1 (fr) 1992-06-11 1993-06-09 Utilisation de l'amidon-iode comme agent de conservation

Country Status (3)

Country Link
EP (1) EP0598896A1 (fr)
JP (1) JPH06510067A (fr)
WO (1) WO1993025268A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591350A (en) * 1994-04-15 1997-01-07 Pall Corporation Iodine disinfection method using a gaseous iodine treated porous medium
US5814225A (en) * 1994-06-09 1998-09-29 Shanbrom Technologies Llc Iodinated gel filtration media for disinfecting protein solutions
US6096216A (en) * 1994-06-09 2000-08-01 American National Red Cross Iodinated matrices for disinfecting biological fluids
US6106773A (en) * 1998-09-24 2000-08-22 American National Red Cross Pathogen inactivating compositions for disinfecting biological fluids
EP1225924B1 (fr) * 1999-10-22 2003-06-18 Shanbrom Technologies, LLC Protection des proteines labiles au cours d'une desinfection a l'iode

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2540170C3 (de) * 1975-09-10 1979-01-18 Basf Ag, 6700 Ludwigshafen Verwendung von in organischer Lösung hergestelltem Polyvinylpyrrolidon zur Herstellung von stabilen wäßrigen PoIyvinylpyrrolidon-Jod-Lösungen
DE3313655C2 (de) * 1983-03-02 1995-03-23 Euro Celtique Sa Pharmazeutisches Jodophor-Präparat
US4971760A (en) * 1986-03-10 1990-11-20 University Of Southern California Novel method for disinfecting red blood cells, blood platelets, blood plasma, and optical corneas and sclerae
US5185371A (en) * 1986-03-10 1993-02-09 University Of Southern California Method for disinfecting red blood cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9325268A1 *

Also Published As

Publication number Publication date
JPH06510067A (ja) 1994-11-10
WO1993025268A1 (fr) 1993-12-23

Similar Documents

Publication Publication Date Title
US5609864A (en) Preservation of blood, tissues and biological fluids
AU644216B2 (en) Preservation of blood, tissues and biological fluids
US5370869A (en) Antimicrobial preservation of platelets and blood factors
US8753807B2 (en) Method for microbes depletion in human blood or full serum using antimicrobial photodynamic laser therapy
AU2081988A (en) Method for eradicating infectious contaminants in tissues
US5591350A (en) Iodine disinfection method using a gaseous iodine treated porous medium
JP2005509654A (ja) 血液の保存に有用な抗病原体組成物
WO1993017693A1 (fr) Compositions albumine-iode utilisee dans la conservation du sang, des tissus et des fluides biologiques
EP0598896A1 (fr) Utilisation de l'amidon-iode comme agent de conservation
AU648823B2 (en) Antimicrobial preservation of plasma
US5985260A (en) Disinfection of blood and biologicals with active albumin-iodine complex
EP0614368A1 (fr) Sang de transfusion humain sans danger
EP0605704A1 (fr) Conservation du sang, de tissus et de fluides biologiques au moyen de peroxyde de complexe amidon-iode
EP0605690A1 (fr) Conservation de sang, de tissus et de fluides biologiques dans du peroxyde d'hydrogene et du povidone
EP0622989A1 (fr) Procede d'inactivation de microbes dans le sang au moyen de l'iode
WO1993004731A1 (fr) Traitement a l'iode-iodure de cellules sanguines rouges
WO1994009635A1 (fr) Utilisation d'amidon-iode peroxyde dans la conservation de produits alimentaires

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19940614

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19950405

R18W Application withdrawn (corrected)

Effective date: 19950405